Inhibitor of apoptosis proteins as promising therapeutic targets in chronic lymphocytic leukemia

ABSTRACT: Inhibitor of apoptosis (IAP) proteins are expressed at high levels in CLL cells and may contribute to evasion of cell death leading to poor therapeutic outcome. Of note, prognostic unfavourable cases with e.g. non-mutated VH-status and TP53 mutation responded significantly better to BV6 than samples with unknown or favourable prognosis e.g. 13q deletion. The majority of cases with 17p deletion (10/12) and Fludarabine refractory cases were sensitive to BV6, indicating that BV6 acts independently of the p53 pathway. Importantly, BV6 dose-dependently induced cell death in 28 of 51 (54%) investigated patient samples while B cells from healthy donors were largely unaffected. BV6 also triggered cell death under survival conditions mimicking the microenvironment e.g. by adding CD40 ligand or in c

ORGANISM(S): Homo sapiens

SUBMITTER: Lars Bullinger 

PROVIDER: E-GEOD-62533 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress